Alteogen Healthcare appointed Ko Jin-kook as the company’s CEO at Monday's board of directors meeting.
Alteogen Healthcare’s new CEO, Ko Jin-kook
CEO Ko graduated from the Yonsei University Department of Biomedical Engineering and completed an MBA course at the Yonsei University Graduate School of Business. He was in charge of marketing and sales at LG Chem. He experienced the launch of various new products at Janssen Korea, the pharmaceutical division of global pharmaceutical giant Johnson & Johnson (J&J).
With this experience and competence, he joined Alteogen Healthcare as its vice president. Alteogen Healthcare is a subsidiary in charge of sales and marketing of Alteogen's products, starting with Tergase Injection and future developments, and was appointed its CEO this year.
Former CEO Lee Jae-sang will support the company's growth as an advisor.
“Based on the unique technology and market competitiveness of Tergase, the first genetically recombinant hyaluronidase in Korea, we will focus on achieving the No. 1 position in Korea and expanding into the global market and expanding business areas,” Ko said.
Alteogen Healthcare is currently in charge of the sales and marketing of growth hormone, the anti-adhesion agent Protescal, and the hyaluronidase product Tergase.
Tergase has passed the Drug Committee (DC) of more than 40 general hospitals, including Asan Medical Center and Kyungpook National University Hospital, after receiving a sales license from the Ministry of Food and Drug Safety late last year. In addition, PharmaResearch is conducting joint promotions by dealing with hospitals.